Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $16.63B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 384.69B 19.14B Mar/2026
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
ALKERMES USD 5.88B 1.26B Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Cytokinetics USD 8.19B 420M Mar/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 10.89B 857M Mar/2026
Gilead Sciences USD 172.99B 20.71B Mar/2026
Halozyme Therapeutics USD 7.66B 257M Mar/2026
Incyte USD 18.73B 660M Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Nektar Therapeutics USD 11.91B 11.05B Jun/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Repligen USD 6.64B 2.58B Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Teva Pharmaceutical Industries USD 34.27B 2.14B Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026